MX2020003664A - Metodos de reduccion de efectos secundarios del tratamiento con conjugado anticuerpo anti-cd30-farmaco. - Google Patents
Metodos de reduccion de efectos secundarios del tratamiento con conjugado anticuerpo anti-cd30-farmaco.Info
- Publication number
- MX2020003664A MX2020003664A MX2020003664A MX2020003664A MX2020003664A MX 2020003664 A MX2020003664 A MX 2020003664A MX 2020003664 A MX2020003664 A MX 2020003664A MX 2020003664 A MX2020003664 A MX 2020003664A MX 2020003664 A MX2020003664 A MX 2020003664A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- drug conjugate
- side effects
- antibody drug
- reducing side
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6867—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of a blood cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
Abstract
La presente descripción se refiere, en general, a métodos para mejorar los efectos adversos en sujetos que reciben tratamiento con un conjugado fármaco anticuerpo anti-CD30, que también reciben opcionalmente quimioterapia concomitante. Los efectos adversos incluyen neuropatía periférica y neutropenia.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762570901P | 2017-10-11 | 2017-10-11 | |
US201762580267P | 2017-11-01 | 2017-11-01 | |
US201862639308P | 2018-03-06 | 2018-03-06 | |
US201862764805P | 2018-08-16 | 2018-08-16 | |
PCT/US2018/055354 WO2019075168A2 (en) | 2017-10-11 | 2018-10-11 | METHODS OF REDUCING SIDE EFFECTS OF DRUG-CONJUGATED DRUG THERAPY ANTI-CD30 |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2020003664A true MX2020003664A (es) | 2020-10-12 |
Family
ID=64477266
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2020003664A MX2020003664A (es) | 2017-10-11 | 2018-10-11 | Metodos de reduccion de efectos secundarios del tratamiento con conjugado anticuerpo anti-cd30-farmaco. |
Country Status (14)
Country | Link |
---|---|
US (1) | US11795229B2 (es) |
EP (1) | EP3694559A2 (es) |
JP (2) | JP2020536916A (es) |
KR (1) | KR20200066676A (es) |
CN (1) | CN111526893A (es) |
AU (1) | AU2018347406A1 (es) |
BR (1) | BR112020006892A2 (es) |
CA (1) | CA3078737A1 (es) |
IL (1) | IL273874A (es) |
MA (1) | MA50767A (es) |
MX (1) | MX2020003664A (es) |
SG (1) | SG11202003352SA (es) |
TW (1) | TW201922281A (es) |
WO (1) | WO2019075168A2 (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20210149964A (ko) | 2020-06-02 | 2021-12-10 | 삼성디스플레이 주식회사 | 표시 패널 및 이를 구비하는 표시 장치 |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4474893A (en) | 1981-07-01 | 1984-10-02 | The University of Texas System Cancer Center | Recombinant monoclonal antibodies |
US4714681A (en) | 1981-07-01 | 1987-12-22 | The Board Of Reagents, The University Of Texas System Cancer Center | Quadroma cells and trioma cells and methods for the production of same |
US4925648A (en) | 1988-07-29 | 1990-05-15 | Immunomedics, Inc. | Detection and treatment of infectious and inflammatory lesions |
US5601819A (en) | 1988-08-11 | 1997-02-11 | The General Hospital Corporation | Bispecific antibodies for selective immune regulation and for selective immune cell binding |
DE69029036T2 (de) | 1989-06-29 | 1997-05-22 | Medarex Inc | Bispezifische reagenzien für die aids-therapie |
DE69120146T2 (de) | 1990-01-12 | 1996-12-12 | Cell Genesys Inc | Erzeugung xenogener antikörper |
ES2129029T5 (es) | 1990-10-05 | 2005-10-16 | Celldex Therapeutics, Inc. | Inmunoestimulacion dirigida con reactivos biespecificos. |
AU8727291A (en) | 1990-10-29 | 1992-06-11 | Cetus Oncology Corporation | Bispecific antibodies, method of production, and uses thereof |
DE69214709T2 (de) | 1991-04-26 | 1997-02-20 | Surface Active Ltd | Neue Antikörper und Verfahren zu ihrer Verwendung |
EP0627940B1 (en) | 1992-03-05 | 2003-05-07 | Board of Regents, The University of Texas System | Use of immunoconjugates for the diagnosis and/or therapy of vascularized tumors |
US7090843B1 (en) | 2000-11-28 | 2006-08-15 | Seattle Genetics, Inc. | Recombinant anti-CD30 antibodies and uses thereof |
US6884869B2 (en) | 2001-04-30 | 2005-04-26 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
EP1545613B9 (en) | 2002-07-31 | 2012-01-25 | Seattle Genetics, Inc. | Auristatin conjugates and their use for treating cancer, an autoimmune disease or an infectious disease |
WO2005084390A2 (en) | 2004-03-02 | 2005-09-15 | Seattle Genetics, Inc. | Partially loaded antibodies and methods of their conjugation |
EP1828241A1 (en) * | 2004-12-23 | 2007-09-05 | Laboratoires Serono S.A. | G-csf polypeptides and uses thereof |
EP2211885B1 (en) * | 2007-10-12 | 2015-07-29 | Seattle Genetics, Inc. | Combination therapy with antibody-drug conjugates |
CA3150199A1 (en) | 2009-01-09 | 2010-07-15 | Seagen Inc. | Weekly dosing regimens for anti-cd30 vc-pab-mmae antibody drug-conjugates |
-
2018
- 2018-10-11 AU AU2018347406A patent/AU2018347406A1/en active Pending
- 2018-10-11 MX MX2020003664A patent/MX2020003664A/es unknown
- 2018-10-11 CA CA3078737A patent/CA3078737A1/en active Pending
- 2018-10-11 TW TW107135857A patent/TW201922281A/zh unknown
- 2018-10-11 BR BR112020006892-6A patent/BR112020006892A2/pt unknown
- 2018-10-11 US US16/755,403 patent/US11795229B2/en active Active
- 2018-10-11 WO PCT/US2018/055354 patent/WO2019075168A2/en unknown
- 2018-10-11 JP JP2020520535A patent/JP2020536916A/ja not_active Withdrawn
- 2018-10-11 KR KR1020207012961A patent/KR20200066676A/ko active Search and Examination
- 2018-10-11 CN CN201880075981.2A patent/CN111526893A/zh active Pending
- 2018-10-11 SG SG11202003352SA patent/SG11202003352SA/en unknown
- 2018-10-11 MA MA050767A patent/MA50767A/fr unknown
- 2018-10-11 EP EP18808554.2A patent/EP3694559A2/en active Pending
-
2020
- 2020-04-07 IL IL273874A patent/IL273874A/en unknown
-
2023
- 2023-07-18 JP JP2023116434A patent/JP2023162163A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
SG11202003352SA (en) | 2020-05-28 |
CA3078737A1 (en) | 2019-04-18 |
AU2018347406A1 (en) | 2020-04-23 |
JP2023162163A (ja) | 2023-11-08 |
KR20200066676A (ko) | 2020-06-10 |
US11795229B2 (en) | 2023-10-24 |
MA50767A (fr) | 2020-08-19 |
US20210221901A1 (en) | 2021-07-22 |
CN111526893A (zh) | 2020-08-11 |
WO2019075168A3 (en) | 2019-05-23 |
WO2019075168A2 (en) | 2019-04-18 |
EP3694559A2 (en) | 2020-08-19 |
BR112020006892A2 (pt) | 2020-10-06 |
JP2020536916A (ja) | 2020-12-17 |
TW201922281A (zh) | 2019-06-16 |
IL273874A (en) | 2020-05-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CR20190376A (es) | Formulaciones de anticuerpos de her2 subcutáneas | |
BR112018073574A2 (pt) | conjugados de anticorpo-fármaco anti-cmet e métodos para a sua utilização | |
MX2019012464A (es) | Terapia combinada con un conjugado de anticuerpo y farmaco anti-axl. | |
CL2018001646A1 (es) | Conjugados de anticuerpos anti-drosophila similar a delta 3 (anti-dll3) y medicamentos para usarse en el tratamiento contra melanoma. (divisional solicitud 201602105) | |
MX2018002723A (es) | Macrociclicos peptidomimeticos y usos de los mismos. | |
CR20190350A (es) | INHIBIDORES DE TGFß1 ISOFORMA-ESPECÍFICOS CONTEXTO-PERMISIVOS Y USO DE LOS MISMOS | |
BR112015027281A2 (pt) | combinações de dosagens para reduzir respostas imunológicas humorais indesejadas | |
BR112015019064A8 (pt) | uso de uma composição compreendendo nanopartículas compreendendo paclitaxel e uma albumina para o tratamento de melanoma e kit | |
MX2019010757A (es) | Métodos y composiciones relacionados con el tratamiento combinado con antiinflamatorios y nanoportadores sintéticos que comprenden un inmunosupresor. | |
MX2019012465A (es) | Terapia combinada con un conjugado de anticuerpo y farmaco anti-cd25. | |
BR112021016296A2 (pt) | Formulações tópicas de rapamicina e seu uso em tratamento de angiofibromas faciais e outros distúrbios de pele | |
EA201890457A1 (ru) | Комбинации антитела против ox40 и модулятора tlr4 и их применение | |
AR120147A1 (es) | Anticuerpos anti-pd-l1 y conjugados anticuerpo-fármaco | |
MX2020004563A (es) | Metodos de reduccion de efectos secundarios del tratamiento con conjugado anticuerpo anti-cd30-farmaco. | |
MX2021002633A (es) | Dispersiones solidas de bendamustina e infusion continua. | |
MX2020003664A (es) | Metodos de reduccion de efectos secundarios del tratamiento con conjugado anticuerpo anti-cd30-farmaco. | |
BR112018014723A2 (pt) | fantasmas bacterianos para o tratamento de câncer | |
MX2019005309A (es) | Anticuerpos anti-bag3 en combinacion con inhibidores del punto de control inmunitario para uso terapeutico. | |
EA202191165A1 (ru) | Элацестрант в комбинации с абемациклибом у женщин с раком молочной железы | |
MX2021003734A (es) | Métodos de tratamiento del linfoma de linfocitos t periférico mediante terapia con conjugado fármaco-anticuerpo anti-cd30. | |
EA202090966A1 (ru) | МОНОКЛОНАЛЬНЫЕ АНТИ-TrkB АНТИТЕЛА И СПОСОБЫ ИХ ПРИМЕНЕНИЯ | |
BR112017028012A2 (pt) | Terapia combinada com um conjugado anticorpo- fármaco anti-her2 e um inibidor de bcl-2 | |
AR113554A1 (es) | Métodos de reducción de efectos secundarios del tratamiento con conjugado de anticuerpo anti-cd30-fármaco | |
EA202090909A1 (ru) | Способы уменьшения побочных эффектов терапии конъюгатом анти-cd30 антитело-лекарственное средство | |
AR113981A1 (es) | Nano-partículas que contienen el gangliósido gm3 como inmunomoduladoras |